Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Alzheimer's Disease
Interventions
DRUG

CS6253 Solution for Injection

Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)

DRUG

Placebo

Physiological saline solution for intra-venous injection

Trial Locations (1)

28046

La Paz University Hospital, Madrid

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Artery Therapeutics, Inc.

INDUSTRY

NCT05965414 - Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers | Biotech Hunter | Biotech Hunter